Capricor Therapeutics Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Capricor Therapeutics Inc 's ROA in the first quarter of 2026?
Capricor Therapeutics Inc recorded a cumulative net loss of $-115 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -48.65%.

However, within the Healthcare sector 557 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3916, from total ROA ranking in the fourth quarter of 2025 at 4639.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	112.19 %	109.45 %	37.23 %	248.95 %	211.86 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-115	-105	-82	-70	-55
Return On Assets (TTM)	-48.65 %	-54.59 %	-56.18 %	-50.95 %	-48.5 %
CAPR's Total Ranking	# 3916	# 4639	# 4079	# 4086	# 4130
Total Assets (TTM) in million	326	356	126	134	154
Seq. Total Assets Change	-8.33 %	181.52 %	-5.34 %	-13.13 %	-9.52 %
Seq. Net Income Change	-	-	-	-	-

CAPR's 5 Years Annual ROA >> Back to CAPR Management Effectiveness >> Compare CAPR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 239
Sector	# 558
Overall	# 3881

Return On Assets Statistics
High	Average	Low
16.11 %	-59.9 %	-127.92 %
(Dec 31 2017)		(Jun 30 2019)

News about Capricor Therapeutics inc Return on Assets ROA

In a groundbreaking presentation at the 2024 World Muscle Society Congress, Capricor Therapeutics, a trailb...

Innovative Therapies in Neuromuscular Disorders: Capricor Therapeutics Presents Promising Long-term Data on Deramcicel for Duchenne Muscular Dystrophy In a groundbreaking presentation at the 2024 World Muscle Society Congress, Capricor Therapeutics, a trailblazer in advancing cell and exosome-based therapies for rare and life-threatening diseases, unveiled compelling long-term data from their HOPE-2 Open Label Extension (OLE) study. The study focused on the continued efficacy and safety of deresmocel, a cutting-edge therapeutic developed to combat Duchenne Muscular Dystrophy (DMD) a severe genetic disorder marked by progressive muscle degeneration and weakness due to alterations in the dystrophin protein.The new data released at this prestigious international forum highlighted the sustained benefit of deresmocel in managing symptoms associated with DMD. Over the extended period of observation, patients treated with deresmocel demonstrated marked improvements in muscle function and stability, accentuating the potential of this novel therapeutic approach to transform the clinical landscape for DMD.

Capricor Therapeutics Advances Towards a New Dawn in Duchenne Muscular Dystrophy Treatment with Deramiocel

In the ever-evolving landscape of biopharmaceutical innovation, hope often hinges on the breakthroughs of tomorrow. Capricor Therapeutics, a pioneering company in the realm of advanced therapeutic modalities, has announced an exciting development that could significantly impact the lives of individuals suffering from Duchenne Muscular Dystrophy (DMD) cardiomyopathy. The company has initiated a rolling submission for a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for its groundbreaking drug, Deramiocel. This therapeutic advance marks a significant milestone in the quest to address one of the most debilitating manifestations of DMD.DMD is a rare genetic disorder characterized by progressive muscle degeneration and weakness, predominantly affecting young boys. One of the tragic complications of this condition is DMD cardiomyopathy, a severe form of heart muscle disease that jeopardizes the lives of those affected, often leading to premature heart failure. This aspect of the disease has become a critical focus in recent years as researchers and clinicians strive to enhance outcomes for these vulnerable patients.

Financial Statements
Capricor Therapeutics Inc 's Assets	$ 326 million	CAPR's Balance sheet
Capricor Therapeutics Inc 's Income	$ -34 million	Quarterly CAPR's Income Statement
CAPR's Income by Division		See CAPR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	109.45 %	195.99 %	16.05 %	22.98 %	16.22 %
Total Assets in million	356	170	57	49	40
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-105	-40	-22	-29	-20
Annual Return On Assets	-29.51 %	-23.81 %	-38.82 %	-58.65 %	-49.77 %

CAPR's 5 Years Annual ROA >> Back to CAPR Management Effectiveness >> Compare CAPR ROA to its Competitors

More Return On Assets Ratios
CAPR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CAPR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CAPR's Competitors
Subscribers only: Roa for Capricor Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CAPR's Customers

You may also want to know
CAPR's Roi	CAPR's Inventory Turnover Ratio	CAPR's Growth Rates	CAPR's Dividend Comparisons
	CAPR's Profitability Ratios	CAPR's Asset Turnover Ratio	CAPR's Dividend Growth
CAPR's Roe	CAPR's Valuation Ratios	CAPR's Financial Strength Ratios	CAPR's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-08-30T14:47:28+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.